Caris Life Sciences, Inc. (CAI) AI Stock Analysis

• Market Cap: $7.55B
• Dividend Yield: N/A
• Average Volume (3M): 728.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.78
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 1,769
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.08
• Shares Outstanding: 282,146,900
• 10 Day Avg. Volume: 691,794
• 30 Day Avg. Volume: 728,283
• PEG Ratio: -0.52
• Price to Book (P/B): -2.85
• Price to Sales (P/S): 17.30
• P/FCF Ratio: -28.11
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 13.88
• Enterprise Value/Gross Profit: 22.65
• Enterprise Value/Ebitda: -83.58
• 1Y Price Target: $37.60
• Price Target Upside: 40.82% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $26.00 ▼(-2.62% Downside)

Caris Life Sciences' overall stock score is primarily impacted by its challenging financial performance, including negative equity and profitability issues. Despite strong earnings call results with record-breaking revenue growth and improved margins, the stock's technical indicators and valuation remain weak.

Positive Factors

Revenue Growth

The significant revenue growth reflects strong demand for Caris' services, indicating robust market position and potential for sustained expansion.

Improved Gross Margins

Improved gross margins suggest enhanced operational efficiency and pricing power, contributing to better profitability and financial health.

Strong Balance Sheet

A strong cash position provides strategic flexibility for investments in technology and product development, supporting long-term growth.

Negative Factors

Negative Equity Position

Negative equity indicates financial instability, which could limit the company's ability to secure financing and invest in growth opportunities.

Cash Flow Challenges

Negative operating cash flow suggests difficulties in covering operational expenses, potentially impacting the company's ability to sustain operations.

Dependency on Revenue True-Ups

Reliance on revenue true-ups for financial performance indicates potential volatility and uncertainty in revenue streams, affecting predictability.

Caris Life Sciences, Inc. Business Overview & Revenue Model

Company Description

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.

How the Company Makes Money

Caris Life Sciences generates revenue through a combination of diagnostic testing services and collaboration with healthcare providers and pharmaceutical companies. The primary revenue stream comes from the sale of its genomic and proteomic profiling tests, which are utilized by oncologists to tailor cancer treatments for individual patients. Additionally, the company engages in partnerships with pharmaceutical companies for biomarker discovery and clinical trial support, which further enhances its revenue. Caris also benefits from reimbursement agreements with insurance providers, allowing for the coverage of its testing services. Furthermore, the company may explore avenues such as licensing agreements and collaborations in research and development, contributing to its overall earnings.

Caris Life Sciences, Inc. Financial Statement Overview

Summary

Caris Life Sciences, Inc. faces significant financial challenges with declining profitability, negative cash flows, and high leverage, indicating financial instability and risks to future growth.

Income Statement

Caris Life Sciences, Inc. has experienced a decline in profitability over recent years, with negative net profit margins and EBIT margins indicating operational challenges. Revenue growth has been inconsistent, with a notable decline in 2020. The company has struggled to maintain positive margins, reflecting difficulties in managing costs relative to revenue.

Balance Sheet

The balance sheet shows significant financial leverage, with a negative stockholders' equity and a high debt-to-equity ratio in earlier years. This indicates potential financial instability and risk. The return on equity has been positive but low, suggesting limited returns for shareholders given the high leverage.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows in recent years, indicating liquidity challenges. The free cash flow to net income ratio is positive, suggesting some efficiency in converting income to cash, but the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2020	Dec 2019
Income Statement
Total Revenue	519.15M	412.26M	306.13M	258.49M	294.01M	416.54M
Gross Profit	318.25M	178.78M	89.31M	80.02M	184.16M	200.51M
EBITDA	-86.22M	-182.95M	-260.80M	-245.89M	254.46M	248.30M
Net Income	-150.05M	-281.89M	-341.42M	-320.83M	27.73M	31.01M
Balance Sheet
Total Assets	984.57M	343.73M	412.90M	717.42M	2.61B	2.90B
Cash, Cash Equivalents and Short-Term Investments	755.49M	66.15M	121.59M	409.62M	132.54M	46.46M
Total Debt	426.74M	424.26M	217.27M	270.87M	1.75B	2.10B
Total Liabilities	506.21M	2.84B	2.56B	2.42B	1.91B	2.21B
Stockholders Equity	478.36M	-2.50B	-2.14B	-1.70B	702.24M	693.24M
Cash Flow
Free Cash Flow	27.20M	-253.64M	-298.42M	-327.96M	57.57M	-65.14M
Operating Cash Flow	38.38M	-245.20M	-276.10M	-285.71M	277.02M	254.00M
Investing Cash Flow	-11.17M	52.93M	214.77M	-282.99M	-33.97M	-271.87M
Financing Cash Flow	661.59M	200.29M	10.13M	10.45M	-249.88M	-108.48M

Caris Life Sciences, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CAI	49 Neutral	$7.55B	-11.01	―	―	―	―
BOLT	49 Neutral	$10.44M	-0.24	-81.97%	―	-46.88%	34.83%
SNSE	40 Underperform	$10.78M	-0.37	-67.47%	―	―	9.63%
MSPR	38 Underperform	$4.04M	―	―	―	-8.57%	-52.17%
INAB	34 Underperform	$7.79M	-0.24	-189.72%	―	―	70.57%

Caris Life Sciences, Inc. Corporate Events

Caris Life Sciences Reports Record Revenue Growth

Caris Life Sciences’ recent earnings call painted a picture of robust financial health and strategic growth, marked by record-breaking revenue and improved profitability metrics. The company celebrated significant achievements, including a strong balance sheet and increased average selling price (ASP). However, challenges such as pharma revenue fluctuations and the intricate process for MRD approval were also acknowledged.

Caris Life Sciences Reports Strong Q3 2025 Growth

Caris Life Sciences, Inc., headquartered in Irving, Texas, is a pioneering AI TechBio company specializing in precision medicine and molecular profiling services to advance healthcare through innovative diagnostic solutions.

Caris Life Sciences Reports Strong Q2 2025 Results

Caris Life Sciences, Inc., a leading AI TechBio company in the precision medicine sector, focuses on developing innovative diagnostic solutions through comprehensive molecular profiling and advanced AI technologies. In its second quarter of 2025 financial results, Caris Life Sciences reported a significant revenue increase of 81.3% to $181.4 million compared to the same period last year. The company also achieved a positive Adjusted EBITDA of $16.7 million and positive net cash flow from operating activities of $7.3 million, indicating strong operational performance.